Tarsus Pharmaceuticals Inc’s recent filing unveils that its insider Farrow Jeffrey S unloaded Company’s shares for reported $0.55 million on Jun 17 ’25. In the deal valued at $40.42 per share,13,608 shares were sold. As a result of this transaction, Farrow Jeffrey S now holds 36,704 shares worth roughly $1.46 million.
Then, Farrow Jeffrey S bought 13,608 shares, generating $550,088 in total proceeds.
Before that, Lin Elizabeth Yeu sold 1,006 shares. Tarsus Pharmaceuticals Inc shares valued at $41,326 were divested by the Chief Medical Officer at a price of $41.08 per share. As a result of the transaction, Lin Elizabeth Yeu now holds 7,694 shares, worth roughly $0.31 million.
Goldman began covering TARS with “Neutral” recommendation on November 20, 2023. William Blair started covering the stock on July 18, 2023. It rated TARS as “an Outperform”.
Price Performance Review of TARS
On Tuesday, Tarsus Pharmaceuticals Inc [NASDAQ:TARS] saw its stock fall -0.60% to $39.69. Over the last five days, the stock has lost -2.02%. Tarsus Pharmaceuticals Inc shares have risen nearly 37.19% since the year began. Nevertheless, the stocks have fallen -28.32% over the past one year. While a 52-week high of $57.28 was reached on 02/05/25, a 52-week low of $20.08 was recorded on 07/08/25.
Levels Of Support And Resistance For TARS Stock
The 24-hour chart illustrates a support level at 38.66, which if violated will result in even more drops to 37.64. On the upside, there is a resistance level at 40.56. A further resistance level may holdings at 41.44.
How much short interest is there in Tarsus Pharmaceuticals Inc?
A steep rise in short interest was recorded in Tarsus Pharmaceuticals Inc stocks on 2025-06-13, growing by 0.33 million shares to a total of 8.11 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 7.78 million shares. There was a rise of 4.09%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 18, 2023 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating .
